RECRUITING

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.

Official Title

Observational, Non-Interventional Study to Determine the Operational Feasibility and Measurement Properties of Endpoints in Patients with Retinal Degeneration

Quick Facts

Study Start:2024-04-05
Study Completion:2026-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06375239

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of bilateral retinitis pigmentosa, choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis or other retinal dystrophies confirmed from previous eye examination records
  2. * Best-corrected visual acuity between 20/70 and HM in at least one eye as tested with clinic-based visual acuity method
  3. * Reasonably fluent in English
  1. * Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.
  2. * Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol
  3. * Current pregnancy as reported by patient

Contacts and Locations

Study Contact

Shawn Yu, OD
CONTACT
949-264-3793
info@vr-ai.com

Study Locations (Sites)

Vision Research and Assessment Institute
Irvine, California, 92612
United States

Collaborators and Investigators

Sponsor: Ray Therapeutics, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-05
Study Completion Date2026-04-30

Study Record Updates

Study Start Date2024-04-05
Study Completion Date2026-04-30

Terms related to this study

Additional Relevant MeSH Terms

  • Retinitis Pigmentosa
  • Choroideremia
  • Stargardt Macular Dystrophy
  • Stargardt Disease
  • Geographic Atrophy from Age-related Macular Degeneration
  • X-lined Retinoschisis
  • Retinal Dystrophies